Liquidia (FRA:LT4) Debt-to-Revenue : 0.15 (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Liquidia Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Liquidia's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €1.13 Mil. Liquidia's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €1.30 Mil. Liquidia's annualized Revenue for the quarter that ended in Sep. 2024 was €16.03 Mil. Liquidia's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.15.

Liquidia Debt-to-Revenue Historical Data

The historical data trend for Liquidia's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Liquidia Debt-to-Revenue Chart

Liquidia Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

3.03

23.17

1.25

1.54

0.20

Liquidia Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Revenue	Get a 7-Day Free Trial															0.26	0.19	0.27	0.20	0.15

Competitive Comparison of Liquidia's Debt-to-Revenue

For the Biotechnology subindustry, Liquidia's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Liquidia's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Liquidia's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Liquidia's Debt-to-Revenue falls into.

Liquidia Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Liquidia's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.044	+	2.168)	/	16.036
	=	0.20

Liquidia's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.125	+	1.299)	/	16.032
	=	0.15

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.

Liquidia Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Liquidia's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Liquidia Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (FRA:LT4) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

LQDA:USA LT4:Germany

Address

419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560

Website

https://www.liquidia.com

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Liquidia Headlines

No Headlines